CTLA4 and neoplasm: Several murine studies have suggested CTLA-4 blockade may impair the suppressive activity of Tregs and deplete Tregs within the tumor microenvironment (TME) via antibody-dependent cell-mediated cytotoxicity (ADCC) resulting in reduced tumor immunosuppression and expansion of effector T cells [46–48].